[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659306":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":27,"studyPopulation":17,"armGroups":28,"interventions":41,"overallOfficials":49,"centralContacts":53,"locations":63,"responsibleParty":85,"collaborators":89,"id":93,"slug":94,"hasResults":95,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":95,"sex":101,"minAge":102,"maxAge":17,"enrollmentInfo":103,"targetDuration":17,"studyType":106,"phases":107,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":66,"whyStopped":17,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},{"fullName":5,"class":6},"University of Michigan","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":17},[9,13],{"measure":10,"description":11,"timeFrame":12},"Tolerability of tributyrin","Tolerability will be defined as the percent of patients that dropped out of the study. (# enrolled at baseline-# enrolled on visit 7)\u002F# enrolled at baseline","Visit 7 (approximately day 90)",{"measure":14,"description":15,"timeFrame":16},"Safety of tributyrin","Safety will be defined as the percent of patients who experienced serious adverse events.","Up to visit 7 (approximately day 90)",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":23,"maskingDescription":17,"whoMasked":24},"DOUBLE",[25,26],"PARTICIPANT","INVESTIGATOR","This is a sub-study of NCT07154511.",[29,35],{"label":30,"type":31,"description":32,"interventionNames":33},"Tributyrin","EXPERIMENTAL","Participants will take 500mg three times a day (TID) tributyrin supplement for 90 days +\u002F- 7 days.",[34],"Drug: Tributyrin",{"label":36,"type":37,"description":38,"interventionNames":39},"Placebo","PLACEBO_COMPARATOR","Participants will take 500mg placebo for 90 days +\u002F- 7 days.",[40],"Drug: Placebo",[42,46],{"type":43,"name":30,"description":44,"armGroupLabels":45,"otherNames":17},"DRUG","Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 90 days +\u002F- 7 days.",[30],{"type":43,"name":36,"description":47,"armGroupLabels":48,"otherNames":17},"Participants will take 500mg TID placebo for 90 days +\u002F- 7 days.",[36],[50],{"name":51,"affiliation":5,"role":52},"Prabesh Kanel, PhD","PRINCIPAL_INVESTIGATOR",[54,59],{"name":55,"role":56,"phone":57,"phoneExt":17,"email":58},"Nathan Alexander","CONTACT","734-998-8422","natealex@med.umich.edu",{"name":60,"role":56,"phone":61,"phoneExt":17,"email":62},"Robert Vangel, BSc","734-936-1168","rvangel@med.umich.edu",[64],{"facility":65,"status":66,"city":67,"state":68,"zip":69,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":77,"contacts":78},"Domino's Farms","RECRUITING","Ann Arbor","Michigan","48105","United States","US",{"type":73,"coordinates":74},"Point",[75,76],-83.74088,42.27756,{"lat":76,"lon":75},[79,80,81,82],{"name":55,"role":56,"phone":57,"phoneExt":17,"email":58},{"name":60,"role":56,"phone":61,"phoneExt":17,"email":62},{"name":51,"role":52,"phone":17,"phoneExt":17,"email":17},{"name":83,"role":84,"phone":17,"phoneExt":17,"email":17},"Nicolaas Bohnen, MD, PhD","SUB_INVESTIGATOR",{"type":86,"investigatorFullName":87,"investigatorTitle":88,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"SPONSOR_INVESTIGATOR","Prabesh Kanel","Research Assistant Professor of Radiology",[90],{"name":91,"class":92},"Farmer Family Foundation","UNKNOWN","100659306","phase-1-tributyrin-for-progressive-supranuclear-palsy-psp-virtual-trial-100659306",false,"NCT07863180","Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial","Tributyrin for PSP: Phase 1b Virtual Trial - Feasibility Study","BUTTER2","Inclusion Criteria:\n\n* Male or Female, age 45 years and over.\n* Diagnosis of PSP-Richardson syndrome (RS) based on Movement Disorder Society (MDS) Criteria, including\n\n  1. Vertical supranuclear gaze palsy.\n  2. Repeated unprovoked falls OR tendency to fall on the pull test within 3 years.\n* Access to the internet and webcam for virtual visits.\n* Presence of a caregiver.\n\nExclusion Criteria:\n\n* Recent history of significant, uncontrolled GI disease such as Gastroesophageal reflux disease, colorectal cancer.\n* Significant metabolic or uncontrolled medical comorbidity.\n* Regular use of typical anti-cholinergic drugs.\n* Women of child-bearing potential, or who are pregnant and\u002For nursing.\n* Suicidal ideation, as indicated by a response of 2 or 3 on question 9 of the Beck Depression Inventory.\n* Any other condition or criterion that, in the opinion of the investigators, would preclude safe and meaningful participation in the study.","ALL","45 Years",{"count":104,"type":105},15,"ESTIMATED","INTERVENTIONAL",[108,109],"PHASE1","PHASE2","This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its safety and tolerability as a potential treatment. The goal of this research study is to see if a similar supplementation regimen and virtual testing is feasible for people with PSP.",[112,113,114],"Parkinson Disease","Multiple System Atrophy","Progressive Supranuclear Palsy(PSP)",[116,117,118,30],"short chain fatty acid","fecal microbiota transplantation","Butyric acid","2026-10-01",{"date":121,"type":122},"2026-10-07","ACTUAL",{"date":124,"type":105},"2026-09",{"date":126,"type":105},"2027-05",{"name":87,"class":6},1]